| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
GeoVax Labs, Inc.$0.76
+0.03 (+3.93%)
D 26Pipeline Score Overvalued Biotech · Clinical
Market Cap
12.64 M
EPS
-21.70
P/E Ratio
-
Value Trade
1.27 M
SEC Financials
Q2 2026Dilution Risk
Revenue
-
R&D Expenses
3.11 M
Total Assets
4.64 M
Total Liabilities
2.88 M
Equity
1.76 M
D/E Ratio
12,345
173.68 %
Week
213.79 %
1 Month
123.31 %
3 Month
-63.7 %
6 Month
-99.82 %
5 Year
-100 %
All Time
Cash Data
Cash Position
3.14 M
Monthly Burn
1.48 M
Runway
2.1 mo
Burn Trend
SEC Filing
Jul 27, 2026
Overview
Volume
175.11 K
52 Week Range
0.96 - 34.75
% held by Insiders
2.38 %
% held by Institutions
12.23 %
Enterprise Value
11.77 M
Total Shares
5.21 M
Short %
2.9 %
Float Shares
5.18 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for GeoVax Labs, Inc.
214Total events
0Upcoming
31Tier-1 (high impact)
2007 – 2018Coverage
Event history 2
TBD
◆Trial InitiationGOVX-B11Trial
Subscribe to view catalyst details
TBD
◆Trial InitiationTrial
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
D26
Pipeline Score $3M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.2x
rNPV / MCap Top 28%
Micro Cap (rank 658 of 913)
Percentile RankGeoVax Labs, Inc. faces pipeline headwinds (26/100), with $809M risk-adjusted pipeline value, led by COVID-19 Vaccine in COVID-19 Infection (Phase 2), across $77B in total addressable markets, but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVID-19 Vaccine Monoclonal antibody | COVID-19 Infection | Phase 2 | NCT04977024 | 14% | $368M | ACTIVE NOT_RECRUITING | 63 | SLOW | D (26) | Dec 1, 2027 | LOW_RISK | LOW May 24, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
GeoVax DNA/MVA Vaccine | HIV | Phase 2a | 2013-10-09 | 93.2% of the DDMM arm; less than 3-fold; 100% to 84% | GeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV New Clinical Data from HVTN 205, a Phase 2a Trial of GeoVax's Preventive HIV Vaccine, Presented at 2013 AIDS Vaccine Meeting Atlanta, GA Read More | |
GeoVax DNA/MVA Vaccine | HIV | Phase 2a | 2013-10-09 | 93.2% of the DDMM arm; less than 3-fold; 100% to 84% | GeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV New Clinical Data from HVTN 205, a Phase 2a Trial of GeoVax's Preventive HIV Vaccine, Presented at 2013 AIDS Vaccine Meeting Atlanta, GA Read More | |
GeoVax DNA/MVA Vaccine | HIV | Phase 2a | 2013-10-09 | 93.2% of the DDMM arm; less than 3-fold; 100% to 84% | GeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV New Clinical Data from HVTN 205, a Phase 2a Trial of GeoVax's Preventive HIV Vaccine, Presented at 2013 AIDS Vaccine Meeting Atlanta, GA Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GOVX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GOVX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GOVXGeoVax Reports 2017 Third Quarter Financial Results a nd Development Program Update s Progress in Multiple Vaccine Programs Including HIV , Zika, Lassa Fever , Malaria, Hepatitis B, and Cancer Immunotherapy ATLANTA, G A
GeoVax Reports 2017 Third Quarter Financial Results and Development Program Updates Progress in Multiple Vaccine Programs Including HIV, Zika, Lassa Fever, Malaria, Hepatitis B, and Cancer Immunotherapy ATLANTA, GA, November 9, 2017 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotec
Read more →GOVXGeoVax Reports 2017 Second Quarter Financial Results and Provides Corporate Update Continued Success and Progress in Vaccine Development Programs for Zika, HIV, Lassa Fever, Ebola, Malaria, Hepatitis B and Cancer ATLANTA
GeoVax Reports 2017 Second Quarter Financial Results and Provides Corporate Update Continued Success and Progress in Vaccine Development Programs for Zika, HIV, Lassa Fever, Ebola, Malaria, Hepatitis B and Cancer ATLANTA, GA, August 7, 2017 - GeoVax Labs, Inc. (OTCQB: GOVX), a
Read more →GOVXGeoVax Reports 2017 First Quarter Financial Results and Development Program Updates Zika Vaccine Demonstrates 100% Protection in Preclinical Lethal Challenge Model Malaria Vaccine Development Initiated with The Burnet In
GeoVax Reports 2017 First Quarter Financial Results and Development Program Updates Zika Vaccine Demonstrates 100% Protection in Preclinical Lethal Challenge Model Malaria Vaccine Development Initiated with The Burnet Institute HIV Vaccine Continues Successful Progress ATLAN
Read more →GOVXGeoVax Reports 2016 Year-End Financial Results ATLANTA, GA
GeoVax Reports 2016 Year-End Financial Results ATLANTA, GA, March 24, 2017 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for the year ended December 31, 2
Read more →GOVXGeoVax Reports 2016 Third Quarter Financial Results and Provides Corporate Update Updates on Multiple Vaccine Programs Including Zika, HIV, Hemorrhagic Fevers, and Cancer ATLANTA, GA, November 11 , 2016 - GeoVax Labs, In
GeoVax Reports 2016 Third Quarter Financial Results and Provides Corporate Update Updates on Multiple Vaccine Programs Including Zika, HIV, Hemorrhagic Fevers, and Cancer ATLANTA, GA, November 11, 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human
Read more →GOVXGeoVax Reports 2016 Second Quarter Financial Results and Provides Corporate Update Ongoing Vaccine Programs in Zika, HIV, Hemorrhagic Fevers, Hepatitis B and Cancer ATLANTA, GA, August 5 , 2016 - GeoVax Labs, Inc. (OTCQB
GeoVax Reports 2016 Second Quarter Financial Results and Provides Corporate Update Ongoing Vaccine Programs in Zika, HIV, Hemorrhagic Fevers, Hepatitis B and Cancer ATLANTA, GA, August 5, 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines
Read more →GOVXGeoVax Reports 2016 First Quarter Financial Results ATLANTA, GA
GeoVax Reports 2016 First Quarter Financial Results ATLANTA, GA, May 4, 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today announced its financial results for the three months ended March 31, 2016. GeoVax reported a net loss for the
Read more →GOVXGeoVax Reports 2015 Year-End Financial Results And Provides Corporate Update ATLANTA, GA
GeoVax Reports 2015 Year-End Financial Results And Provides Corporate Update ATLANTA, GA, March 16, 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, today announced its financial results for
Read more →GOVXGeoVax to Develop Vaccine Against Zika Virus Collaboration with University of Georgia infectious disease researchers will speed development ATLANTA, GA, February 3 , 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnolog
GeoVax to Develop Vaccine Against Zika Virus Collaboration with University of Georgia infectious disease researchers will speed development ATLANTA, GA, February 3, 2016 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that i
Read more →GOVXGeoVax Begins Oncology Immunotherapy Program GeoVax to Apply its MVA-VLP Vaccine Technology to Cancer Immunotherapy Collaborative Research Agreement Signed with University of Pittsburgh ATLANTA, GA, December 8 , 2015 - G
GeoVax Begins Oncology Immunotherapy Program GeoVax to Apply its MVA-VLP Vaccine Technology to Cancer Immunotherapy Collaborative Research Agreement Signed with University of Pittsburgh ATLANTA, GA, December 8, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company de
Read more →GOVXGeoVax Reports 2015 Third Quarter Financial Results ATLANTA, GA
GeoVax Reports 2015 Third Quarter Financial Results ATLANTA, GA, November 12, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines for HIV, Ebola virus and other infectious diseases using its novel platform technology, announced its financial
Read more →GOVXGeoVax Reports 2015 Second Quarter Financial Results and Provides Corporate Update Ebola Vaccine Preclinical Data to be Released Late Summer Clade B HIV Vaccine Clinical Trial (HVTN 114) on Track to Start in Late 2015 HI
GeoVax Reports 2015 Second Quarter Financial Results and Provides Corporate Update Ebola Vaccine Preclinical Data to be Released Late Summer Clade B HIV Vaccine Clinical Trial (HVTN 114) on Track to Start in Late 2015 HIV Vaccine Program for Africa Advancing ATLANTA, GA, Aug
Read more →GOVXGeoVax Reports 2015 First Quarter Financial Results And Provides Corporate Update Ebola/Marburg Vaccine Program Advances with NIH Collaboration; HIV Vaccine Program Proceeding Toward Pivotal Trial ATLANTA, GA, May 13 , 2
GeoVax Reports 2015 First Quarter Financial Results And Provides Corporate Update Ebola/Marburg Vaccine Program Advances with NIH Collaboration; HIV Vaccine Program Proceeding Toward Pivotal Trial ATLANTA, GA, May 13, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology co
Read more →GOVXGeoVax Appoints Industry Veteran to its Board of Directors Randal D. Chase, Ph.D. Brings Extensive Vaccine Background to GeoVax ATLANTA, GA, March 2 3 , 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company dev
GeoVax Appoints Industry Veteran to its Board of Directors Randal D. Chase, Ph.D. Brings Extensive Vaccine Background to GeoVax ATLANTA, GA, March 23, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines against Ebola and Marburg
Read more →GOVXGeoVax Reports 2014 Year-End Financial Results Progress Report Outlined on Ebola/Marburg and HIV Vaccine Programs ATLANTA, GA
GeoVax Reports 2014 Year-End Financial Results Progress Report Outlined on Ebola/Marburg and HIV Vaccine Programs ATLANTA, GA, March 20, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel platform technology, tod
Read more →GOVXGeoVax Announces Equity Financing of Up to $6 Million Funds to be Used to Advance the Company' s Innovative Vaccine Technology and Move its Ebola Vaccine Candidates t oward Human Clinical Testing ATLANTA, GA, February 25
GeoVax Announces Equity Financing of Up to $6 Million Funds to be Used to Advance the Company's Innovative Vaccine Technology and Move its Ebola Vaccine Candidates toward Human Clinical Testing ATLANTA, GA, February 25, 2015 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology c
Read more →GOVXGeoVax Reports 2014 Third Quarter Financial Results ATLANTA, G A
GeoVax Reports 2014 Third Quarter Financial Results ATLANTA, GA, November 11, 2014 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines using its novel DNA/MVA platform technology, today announced financial results and recent developmen
Read more →GOVXGeoVax Announces Initiation of Ebola Vaccine Development Program GeoVax Developing Vaccines for Epidemic Response as Well as for Routine Immunization ATLANTA, GA
GeoVax Announces Initiation of Ebola Vaccine Development Program GeoVax Developing Vaccines for Epidemic Response as Well as for Routine Immunization ATLANTA, GA, October 2, 2014 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing innovative human vaccines us
Read more →GOVXGeoVax Reports 2014 Second Quarter Financial Results and Provides Corporate Update ATLANTA, G A .
GeoVax Reports 2014 Second Quarter Financial Results and Provides Corporate Update ATLANTA, GA., August 7, 2014 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced its financial results for the three and six mo
Read more →GOVXGeoVax Reports 2014 First Quarter Financial Results And Provides Corporate Update ATLANTA, GA
GeoVax Reports 2014 First Quarter Financial Results And Provides Corporate Update ATLANTA, GA, May 1, 2014 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, announced its financial results for the three months ended March 31, 2014 and prov
Read more →GOVXGeoVax Labs Reports 2013 Financial Results and Provides Corporate Update ATLANTA, GA
GeoVax Labs Reports 2013 Financial Results and Provides Corporate Update ATLANTA, GA, March 5, 2014 - GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology company developing innovative, patented HIV/AIDS vaccines, today announced its financial results for the year en
Read more →GOVXGeoVax Announces $1.65M Private Placement ATLANTA, GA
GeoVax Announces $1.65M Private Placement ATLANTA, GA, December 12, 2013 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced today that it has entered into definitive agreements with certain institutional invest
Read more →GOVXGeoVax Reports 2013 Third Quarter Financial Results Completion of Phase 1 therapeutic HIV vaccine trial; data expected in first quarter 2014 Completion of Phase 1 Preventative Vaccine Trial; top-line results expected in
GeoVax Reports 2013 Third Quarter Financial Results Completion of Phase 1 therapeutic HIV vaccine trial; data expected in first quarter 2014 Completion of Phase 1 Preventative Vaccine Trial; top-line results expected in first quarter 2014 ATLANTA, GA., November 12, 2013 - GeoV
Read more →GOVXGeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV New Clinical Data from HVTN 205, a Phase 2a Trial of GeoVax's Preventive HIV Vaccine, Presented at 2013 AIDS Vaccine Meeting Atlanta, GA
GeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV New Clinical Data from HVTN 205, a Phase 2a Trial of GeoVax's Preventive HIV Vaccine, Presented at 2013 AIDS Vaccine Meeting Atlanta, GA, October 9, 2013 GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology compan
Read more →GOVXGeoVax Reports Financial Results for the Second Quarter and First Half 2013 and Provides Clinical Development Update ATLANTA, GA.
GeoVax Reports Financial Results for the Second Quarter and Provides Clinical Development Update ATLANTA, GA., August 12, 2013 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced its financial results for the s
Read more →GOVXGeoVax Labs Reports 2013 First Quarter Financial Results and Provides Clinical Development Update Phase 1/2 HIV Therapeutic Vaccine Trial Fully Enrolled; Data in 2H2013 Phase 1 HIV Prevention Vaccine Trial Enrolling; Stu
GeoVax Labs Reports 2013 First Quarter Financial Results and Provides Clinical Development Update ATLANTA, GA, May 2, 2013 GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing HIV/AIDS vaccines, announced its financial results for the three months ended March 31,
Read more →GOVXGeoVax Labs Reports 2012 Financial Results and Progress Two Ongoing Clinical Trials for Preventive and Therapeutic HIV/AIDS Vaccine Additional Therapeutic Trial to Start in Mid-2013 ATLANTA, GA
GeoVax Labs Reports 2012 Financial Results and Progress Two Ongoing Clinical Trials for Preventive and Therapeutic HIV/AIDS Vaccine Additional Therapeutic Trial to Start in Mid-2013 ATLANTA, GA, March 11, 2013 GeoVax Labs, Inc. (OTCQB: GOVX), an Atlanta-based biotechnology com
Read more →GOVXGeoVax Reports 2012 Third Quarter Financial Results ATLANTA, GA
GeoVax Reports 2012 Third Quarter Financial Results ATLANTA, GA, November 14, 2012 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and treat HIV/AIDS, announced its financial results for the nine months ended September 30, 2012 and provi
Read more →GOVXGeoVax Reports 2012 Second Quarter Financial Results Three HIV/AIDS Vaccine Human Clinical Trials Advancing Phase 2a Trial Data to be Presented at AIDS Vaccine 2012 Conference on September 11 Additional Clinical Trials P
GeoVax Reports 2012 Second Quarter Financial Results ATLANTA, Ga., August 13, 2012 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing vaccines to prevent and fight HIV/AIDS, announced its financial results for the six months ended June 30, 2012 and provided a
Read more →GOVXGeoVax Labs Reports 2012 First Quarter Financial Results Data from Phase 2a Preventive HIV Vaccine Trial Expected in Late 2012 Phase 1/2 Therapeutic Vaccine Trial Patient Enrollment Advancing Unprecedented Preclinical Re
GeoVax Labs Reports 2012 First Quarter Financial Results ATLANTA, GA, May 15, 2012 - GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced its financial results for the three months ended March 31,
Read more →GOVXGeoVax Labs Reports 2011 Financial Results Two Ongoing Clinical Trials for HIV/AIDS Vaccines; Two More Planned for Late 2012 Data from Phase 2a Clinical Trial Expected Later This Year ATLANTA, GA
GeoVax Labs Reports 2011 Financial Results Two Ongoing Clinical Trials for HIV/AIDS Vaccines; Two More Planned for Late 2012 Data from Phase 2a Clinical Trial Expected Later This Year ATLANTA, GA, March 28, 2012 - GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biotech
Read more →GOVXGeoVax Announces Private Placement of $2.2 Million ATLANTA
GeoVax Announces Private Placement of $2.2 Million ATLANTA - March 20, 2012 - GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta - based biopharmaceutical firm developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, announced today that it has ente
Read more →GOVXGeoVax Labs, Inc. Announces Private Offering of Common Stock and Warrants Offering Expected to Be Completed by
GeoVax Labs, Inc. Announces Private Offering of Common Stock and Warrants Offering Expected to Be Completed by January 31, 2012 ATLANTA, GA, January 4, 2012 - GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), announced that it is conducting a private placement offering of up to $1.5 milli
Read more →GOVXGEOVAX LABS, INC. ANNOUNCES NINE MONTH 2011
ANNOUNCES NINE MONTH 2011 FINANCIAL RESULTS ATLANTA, GA, November 10, 2011 - GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm (the "Company") developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced i
Read more →GOVXGeoVax Labs, Inc. Announces Second Quarter Financial Results Clinical Development with HIV/AIDS Vaccine Progresses ATLANTA, Ga.
Announces Second Quarter Financial Results Clinical Development with HIV/AIDS Vaccine Progresses ATLANTA, Ga., August 12, 2011 - GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based, biopharmaceutical firm (the "Company") developing vaccines to prevent and fight Human Immunodefic
Read more →GOVXGeoVax Labs, Inc. Announces First Quarter Financial Results ATLANTA, GA
GeoVax Labs, Inc. Announces First Quarter Financial Results ATLANTA, GA, April 27, 2011 - GeoVax Labs, Inc. (OTCBB: GOVXD), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced its financial results for the three months ended Ma
Read more →GOVXGeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results ATLANTA, GA
GeoVax Labs Reports Fourth Quarter and Year-End 2010 Financial Results ATLANTA, GA, February 25, 2011 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, today announced its financial re
Read more →GOVXGEOVAX LABS, INC. ANNOUNCES NINE MONTH 2010
ANNOUNCES NINE MONTH 2010 FINANCIAL RESULTS ATLANTA, GA, November 9, 2010 GeoVax Labs, Inc. (OTCQB/OTCBB: GOVX), an Atlanta-based biopharmaceutical firm (the Company or GeoVax ) developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infections, today ann
Read more →GOVXGEOVAX LABS, INC. ANNOUNCES SIX MONTH 2010
ANNOUNCES SIX MONTH 2010 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE ATLANTA, Ga., August 5, 2010 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based, biopharmaceutical firm (the Company ) developing vaccines that prevent and fight Human Immunodeficiency Virus (HIV) infe
Read more →GOVXGEOVAX LABS
GEOVAX LABS, INC. FINANCING UPDATE ATLANTA, GA, July 28, 2010 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based, biopharmaceutical firm (the Company ) developing human vaccines and therapeutics for diseases caused by HIV-1 (Human Immunodeficiency Virus), previously announced
Read more →GOVXGeoVax Labs Announces Postponement of Public Offering ATLANTA, GA
GeoVax Labs Announces Postponement of Public Offering ATLANTA, GA, June 30, 2010 GeoVax Labs, Inc. (OTCBB: GOVX), a biotechnology company dedicated to developing vaccines that prevent and fight human immunodeficiency virus (HIV), today announced that it has decided to postpone
Read more →GOVXGEOVAX LABS ANNOUNCES REVERSE STOCK SPLIT; APPLIES FOR LISTING ON NASDAQ 1:50 Reverse Split to be Effective After Market Close on
GEOVAX LABS ANNOUNCES REVERSE STOCK SPLIT; APPLIES FOR LISTING ON NASDAQ 1:50 Reverse Split to be Effective After Market Close on April 27, 2010 Ticker Symbol to Change from GOVX to GOVXD for 20 Days ATLANTA, Ga., April 16, 2010 GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a
Read more →GOVXAt the Company: Robert McNally, President CEO (678) 384-7220 or rmcnally@geovax.com At The Investor Relations Group: Investor Relations James Carbonara / Jason Strominger or Public Relations Janet Vasquez / Robin
Robert McNally, President CEO (678) 384-7220 or rmcnally@geovax.com At The Investor Relations Group: James Carbonara / Jason Strominger Janet Vasquez / Robin O Malley MONDAY, MARCH 30, 2010 GEOVAX LABS GRANTED ALLOWANCE BY FDA TO START PHASE 1 CLINICAL TRIAL FOR HIV/AIDS T
Read more →GOVXAt The Company: Robert McNally 678.384.7220 or rmcnally@geovax.com At Financial Relations Board: Leslie Loyet Investor Relations 312.640.6672 or lloyet@mww.com Nikki Snodgrass Media Relations 312.640.6732 or nsn
Contact: At The Company: Robert McNally 678.384.7220 or rmcnally@geovax.com At Financial Relations Board: Leslie Loyet Investor Relations 312.640.6672 or lloyet@mww.com Nikki Snodgrass Media Relations 312.640.6732 or nsnodgrass@mww.com MONDAY, MARCH 1, 2010
Read more →GOVXAt The Company: Robert McNally 678.384.7220 or rmcnally@geovax.com At Financial Relations Board: Leslie Loyet Investor Relations 312.640.6672 or lloyet@mww.com Nikki Snodgrass Media Relations 312.640.6732 or ns
678.384.7220 or rmcnally@geovax.com At Financial Relations Board: 312.640.6672 or lloyet@mww.com 312.640.6732 or nsnodgrass@mww.com FRIDAY, NOVEMBER 6, 2009 GEOVAX LABS, INC. PROVIDES THIRD QUARTER 2009 FINANCIAL RESULTS AND OPERATIONAL UPDATE ATLANTA, November 6, 2009 Ge
Read more →GOVXAt The Company: Robert McNally 404.727.0971 or rmcnally@geovax.com At Financial Relations Board: Leslie Loyet Investor Relations 312.640.6672 or lloyet@mww.com Nikki Snodgrass Media Relations 312.640.6732 or nsn
404.727.0971 or rmcnally@geovax.com At Financial Relations Board: 312.640.6672 or lloyet@mww.com 312.640.6732 or nsnodgrass@mww.com MONDAY, SEPTEMBER 21, 2009 GEOVAX LABS REQUESTS PRE-IND MEETING WITH FDA Protocol Submitted for Phase 1 Therapeutic HIV/AIDS Vaccine Trial AT
Read more →GOVXGEOVAX SIGNS HIV/AIDS VACCINE PROPOSAL WITH HEALTH AND HOSPITAL SYSTEM OF COOK COUNTY
GEOVAX SIGNS HIV/AIDS VACCINE PROPOSAL WITH HEALTH AND HOSPITAL SYSTEM OF COOK COUNTY, ILLINOIS ATLANTA, GA, June 18, 2009 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biopharmaceutical company developing human vaccines for diseases caused by the HIV 1 (Human Immunodefic
Read more →GOVXFinancial Relations Board Leslie Loyet 312.640.6672 or lloyet@mww.com At The Company Robert McNally 404.727.0971 or rmcnally@geovax.com FOR IMMEDIATE RELEASE GeoVax Labs, Inc. Announces First Quarter Financial R
Financial Relations Board 312.640.6672 or lloyet@mww.com 404.727.0971 or rmcnally@geovax.com GeoVax Labs, Inc. Announces First Quarter Financial Results ATLANTA, GA, May 7, 2009 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology company focused on development o
Read more →GOVXFinancial Relations Board Leslie Loyet 312.640.6672or lloyet@mww.com At The Company Bob McNally 404.727.0971 or bmcnally@geovax.com GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results AT
Financial Relations Board 312.640.6672or lloyet@mww.com 404.727.0971 or bmcnally@geovax.com GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2008 Financial Results ATLANTA, GA, March 12, 2009 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology company focu
Read more →GOVXFinancial Relations Board Tim Grace 312.640-6667 or tgrace@mww.com At The Company Bob McNally 404.727.0971 or bmcnally@geovax.com GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA Trials
Financial Relations Board 312.640-6667 or tgrace@mww.com 404.727.0971 or bmcnally@geovax.com GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA Trials in South America to Follow ATLANTA February 20, 2009 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-bas
Read more →GOVXGeo Vax Labs, Inc. Add 1 Contacts: At Financial Relations Board: Tim Grace 312.640-6667 or tgrace@mww.com At GeoVax: Robert McNally, Ph.D. 404.727.0971 or bmcnally@geovax.com GEOVAX UPDATE PROVIDED AT THE BIO CEO INVESTO
Contacts: At Financial Relations Board: Tim Grace 312.640-6667 or tgrace@mww.com At GeoVax: Robert McNally, Ph.D. 404.727.0971 or bmcnally@geovax.com GEOVAX UPDATE PROVIDED AT THE BIO CEO INVESTOR CONFERENCE 2009 ATLANTA February 11, 2009 GeoVax Labs, Inc. (OTC B
Read more →GOVXMelanie Nimrodi, Media Contact 312.546.3508 mnimrodi@frbir.com At the Company: Robert McNally / Jennifer Nelms 404.727.0971 FOR IMMEDIATE RELEASE GEOVAX LABS, INC. ANNOUNCES THIRD QUARTER 2008
Melanie Nimrodi, Media Contact Robert McNally / Jennifer Nelms GEOVAX LABS, INC. ANNOUNCES THIRD QUARTER 2008 FINANCIAL RESULTS AND PROVIDES OPERATIONAL UPDATE ATLANTA, November 10, 2008 GeoVax Labs, Inc. (OTCBB: GOVX) ( GeoVax or the Company ), a biopharmaceutical firm deve
Read more →GOVXFinancial Relations Board Melanie Nimrodi 312.546.3508 or mnimrodi@frbir.com At The Company Bob McNally 404.727.0971 or bmcnally@geovax.com FOR IMMEDIATE RELEASE GeoVax s DNA and MVA Vaccines Shipped to HIV Vacc
Financial Relations Board 312.546.3508 or mnimrodi@frbir.com 404.727.0971 or bmcnally@geovax.com GeoVax s DNA and MVA Vaccines Shipped to HIV Vaccine Trials Network for Use in the Upcoming Phase 2a Trial ATLANTA October 20, 2008 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta b
Read more →GOVXMelanie Nimrodi, Media Contact 312.546.3508 mnimrodi@frbir.com At the Company: Robert McNally / Jennifer Nelms 404.727.0971 FOR IMMEDIATE RELEASE GeoVax Appoints Mr. Peter M Tsolinas to its Board of Directors AT
Melanie Nimrodi, Media Contact Robert McNally / Jennifer Nelms GeoVax Appoints Mr. Peter M Tsolinas to its Board of Directors ATLANTA, GA, August 20, 2008 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta based biopharmaceutical company developing human vaccines for diseases cause
Read more →GOVXMelanie Nimrodi, Media Contact 312.546.3508 mnimrodi@frbir.com At the Company: Robert McNally / Jennifer Nelms 404.727.0971 FOR IMMEDIATE RELEASE GeoVax Labs, Inc. Announces Six Month Financial Results and Provi
Contact: Melanie Nimrodi, Media Contact 312.546.3508 mnimrodi@frbir.com At the Company: Robert McNally / Jennifer Nelms 404.727.0971 GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update ATLANTA, Ga., August 11, 2008 GeoVax Labs,
Read more →GOVXGEOVAX VIVALIS Media Contact: Melanie Nimrodi Media Contact: Steve Grobet/Emmanuel Huynh 1 312.546.3508 33 (0) 1 44 71 94 91 mnimrodi@frbir.com vivalis@newcap.fr Company Contact: Company Contact: Robert McNally / Jennife
GEOVAX VIVALIS Media Contact: Melanie Nimrodi Media Contact: Steve Grobet/Emmanuel Huynh 1 312.546.3508 33 (0) 1 44 71 94 91 mnimrodi@frbir.com vivalis@newcap.fr Company Contact: Company Contact: Robert McNally / Jennifer Nelms Franck Grimaud 1 404.727.0971 investors@vival
Read more →GOVXMelanie Nimrodi, Media Contact 312.546.3508 mnimrodi@frbir.com At the Company: Robert McNally / Jennifer Nelms 404.727.0971 FOR IMMEDIATE RELEASE GeoVax Reports Progress On Its AIDS Vaccine Technology ATLANTA, G
Contact: Melanie Nimrodi, Media Contact 312.546.3508 mnimrodi@frbir.com At the Company: Robert McNally / Jennifer Nelms 404.727.0971 GeoVax Reports Progress On Its AIDS Vaccine Technology ATLANTA, GA, July 7, 2008 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta based
Read more →GOVXMEDIA INFORMATION FOR IMMEDIATE RELEASE Contact Information At GeoVax Labs, Inc. At Financial Relations Board Robert McNally or Melanie Nimrodi: 312-546-3508 Jennifer Nelms mnimrodi@frbir.com or 404-727-0971 Tim Grace: 3
FORM 8-K EXHIBIT 99.1 At GeoVax Labs, Inc. At Financial Relations Board Robert McNally or Melanie Nimrodi: 312-546-3508 Jennifer Nelms mnimrodi@frbir.com or 404-727-0971 Tim Grace: 312-640-6667 tgrace@frbir.com GEOVAX SECURES $10 MILLION FINANCING COMMITMENT ATLANTA, GA,
Read more →GOVXAT THE COMPANY Donald Hildebrand / Jennifer Nelms (404) 727-0971 / info@geovax.com FOR IMMEDIATE RELEASE GeoVax Further Strengthens Management Team ATLANTA, Ga., 24 March 2008 GeoVax Labs, Inc. (OTC BB: GOVX), www.geovax
Donald Hildebrand / Jennifer Nelms (404) 727-0971 / info@geovax.com GeoVax Further Strengthens Management Team Ga., 24 March 2008 GeoVax Labs, Inc. (OTC BB: GOVX), www.geovax.com, an Atlanta based AIDS vaccine development company is very pleased to announce the addition of D
Read more →GOVXTim Grace, Investor Contact 312.640.6667 Melanie Nimrodi, Media Contact 312.546.3508 mnimrodi@frbir.com At the Company: Donald Hildebrand / Jennifer Nelms 404.727.0971 GeoVax Labs, Inc. Reports Fourth Quarter an
Tim Grace, Investor Contact Melanie Nimrodi, Media Contact Donald Hildebrand / Jennifer Nelms GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results ATLANTA, Ga., March 14, 2008 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based biotechnology company f
Read more →GOVXAT THE COMPANY Donald Hildebrand/Jennifer Nelms (404) 727-0971 FOR IMMEDIATE RELEASE 02 November 2007 Excellent Results Received from GeoVax s Full-Dose HIV/AIDS Vaccine Trial ATLANTA, Ga., 02 Nov 2007 GeoVax Labs, Inc.
Donald Hildebrand/Jennifer Nelms Excellent Results Received from GeoVax s Full-Dose HIV/AIDS Vaccine Trial ATLANTA, Ga., 02 Nov 2007 GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta based biotechnology company, announced today excellent safety and immunogenicity data from its full
Read more →Competitive Position
How GOVX ranks across every disease it competes inCompetitive Position is a premium feature
See how GOVX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial